. "P\u0159\u00EDprava nov\u00FDch radiofarmak na b\u00E1zi monoklon\u00E1ln\u00EDch a rekombinantn\u00EDch protil\u00E1tek a peptid\u016F zna\u010Den\u00FDch alfa a beta radionuklidy" . "monoclonal antibodies;radioactive labeling;123-iodine;211-astatine;bismuth isotepes;nuclear medicine;scintigraphy;targeted therapy"@en . "nuclear medicine" . . "C\u00EDlem projektu bylo ov\u011B\u0159it vlastnosti radioaktivn\u011B ozna\u010Den\u00FDch monoklon\u00E1ln\u00EDch syst\u00E9m\u016F s TU-20 a MEM-97. Byly vyvinuty metody zna\u010Den\u00ED vybran\u00FDmi radionuklidy a kontroln\u00ED metody pro ozna\u010Den\u00E9 protil\u00E1tky. Byly provedeny pilotn\u00ED studie biodistribuce."@cs . "IBS1048301" . . . . "Preparation of new radiopharmaceuticals based on monoclonal and recombinant antibodies and peptides labelled by alpha and beta radionuclides"@en . . "The objective of the project was to examine radiolabeled monoclonal antibody systems with TU-20 and MEM-97. Labeling methods using selected radionuclides and QC methods for labeled antibodies were developed. Pilot biodistribution studies were performed."@en . . . . "http://www.isvav.cz/projectDetail.do?rowId=IBS1048301"^^ . "radioactive labeling" . . . . "monoclonal antibodies" . . . "scintigraphy" . . . . . "bismuth isotepes" . "2"^^ . . "3"^^ . "0"^^ . "123-iodine" . "3"^^ . "211-astatine" . "A. V\u00FDb\u011Br vhodn\u00FDch monoklon\u00E1ln\u00EDch protil\u00E1tek a jejich seFv fragment\u016F. Jako prvn\u00ED budou systematicky prov\u011B\u0159ov\u00E1ny tyto MABs a jejich fragmenty: TU-20, protil\u00E1tka proti neuron specifick\u00E9mu tubulinu; MEM-97, protil\u00E1tka specifick\u00E1 pro leukocyt\u00E1rn\u00ED antigen (CD20). B. Vypracov\u00E1n\u00ED metodiky p\u0159\u00EDpravy alfa radionuklid\u016F a vypracov\u00E1n\u00ED metodik zna\u010Den\u00ED cel\u00FDch molekul protil\u00E1tek i jejich Fv fragment\u016F vybran\u00FDmi alfa-radionuklidy a beta-radionuklidy. C. Ov\u011B\u0159en\u00ED stability p\u0159ipraven\u00FDch radiofarmak a test zachov\u00E1n\u00ED biologick\u00FDch vlastnost\u00ED pou\u017Eit\u00FDch protil\u00E1tek. D. Pilotn\u00ED studie biodistribuce. Na v\u00FD\u0161e popsan\u00FD projekt bude navazovat preklinick\u00E9 ov\u011B\u0159ov\u00E1n\u00ED z\u00EDskan\u00FDch radiofarmak, zaji\u0161t\u011Bn\u00ED podm\u00EDnek pro v\u00FDrobu jak monoklon\u00E1ln\u00EDch protil\u00E1tek, tak i jejich fragment\u016F a kone\u010Dn\u00FDch l\u00E9kov\u00FDch forem podle po\u017Eadavk\u016F spr\u00E1vn\u00E9 v\u00FDrobn\u00ED praxe." . . . "2006-06-19+02:00"^^ . "1"^^ . "A. Choice of approppriate monoclonal antibodies (MABs) and their scFv fragments. The following MABs and their fragments will be examined in the first step: TU-20, an antibody against neuron-specific tubuline, MEM-97, an antibody specific for leukocyte antigen (CD20). B. Development of methods for alpha-radionuclides production and development of methods for labeling the complete MABs or their scFv fragments by selected alpha and/or beta radionuclides. C. Verification of stability of the radiopharmaceuticals obtained and testing of conservation of biological properties of the original MABs. D. A pilot biodistribution study. The above described project will be continued by a preclinical assay of the radipharmaceuticals developed, followed by assuring the production of MABs/their fragments and production of final medical products according the GMP concept."@en .